Q1 2026 earnings call highlights: raised olezarsen peak sales to $3B+, updated guidance, and key PDUFA dates—read the takeaways now.

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items.

The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition where triglyceride levels are significantly elevated ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), a rare ...

HC Wainwright initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a commercial-stage biotech company focused on RNA-targeted therapeutics. Analyst Mitchell Kapoor says Ionis has used its RNA technology to develop a wide range of drugs.

Biogen, Ionis, and Regeneron reported better-than-expected Q1 2026 results, highlighting revenue gains from new products and strategic pipeline progress. Biogen beat earnings forecasts but lowered its full-year outlook due to acquisition-related costs ...